Article thumbnail
Location of Repository

Comparison of the efficacy of p5+14 and peptide G2 to reduce MCMV infection in vitro.

By Pranay Dogra (740848), Emily B. Martin (418059), Angela Williams (292362), Raphael L. Richardson (740849), James S. Foster (740850), Nicole Hackenback (740851), Stephen J. Kennel (288001), Tim E. Sparer (740852) and Jonathan S. Wall (287997)


<p>Peptides G2 and p5+14 were added at different concentrations (100, 10, 1 μM) in a plaque reduction assay as described in materials and methods. Bars represent the average of the percent reduction in infection compared to PBS-treated control from three independent experiments with at least three replicates in each + SD. Statistical significance is indicated as: * = p<0.05, ** = p<0.01, *** = p<0.001, NS = non-significant difference in the reduction of infection compared to PBS-treated control wells.</p

Topics: Biological Sciences, CMV infection, adjunct therapy, infection increases morbidity, nucleoside analogues, CMV adsorption, Lys residues, peptide binding, stage AIDS patients, hearing loss, herpes simplex virus 1, Blocking Herpesvirus Entry Human cytomegalovirus, use HSPGs, attachment receptor, adsorption phase, neutralizing effect, cell surface, mcmv, hcmv, murine CMV, Current treatments, CMV infection cycle
Year: 2015
DOI identifier: 10.1371/journal.pone.0126239.g006
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.